Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts

Plantar Wart Clinical Trial

Official title:

Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05520658
• Other study ID #: Soh-Med-22-07-01
• Status: Recruiting
• Phase: N/A
• Start date: July 1, 2022
• Est. completion date: September 2022

Study information

• Verified date: August 2022
• Source: Sohag University
• Contact: samah R Ahmed, resident
• Phone: 01128636414
• Email: samah_ragab_post[@]med.sohag.edu.eg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Warts are common skin infections caused by human papillomavirus (HPV), which can cause a variety of skin presentations according to its type, site and the immune status .Nongenital warts may be presented as common, plane, plantar, filiform, or mucosal warts .Most people are affected by cutaneous warts, either plantar warts or common warts .prevalence of skin warts is between 3% and 13% and plantar warts are about 30% of skin warts in western world .Majority of cases occur in adolescent and young adults

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: September 2022
• Est. primary completion date: September 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age:>18 years .

• Sex: both males and females will be included.

• Confirmed diagnosis by clinical and dermoscopic examination of plantar warts will be made

Exclusion Criteria:

• Patients with history or evidenced hypersensitivity to any component used in this study.

• Pregnancy & lactating.

• Patients who receive immune suppressive therapy.

• Patients who receive any wart treatment during the last 2 months before enrollment in the study.

• Patients with systemic illness especially cardiac patients.

• Patients who refused participation in the study

Related Conditions & MeSH terms

• Foot Diseases
• Plantar Wart
• Warts

Intervention

Drug:
• combined digoxin and furosemide
one session every 2 weeks for maximum 6 sessions
• 5 fluorouracil
5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks for maximum 6 sessions .

Locations

Country	Name	City	State
Egypt	Sohag University Hospital	Sohag

Sponsors (1)

Lead Sponsor	Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

References & Publications (2)

Abeck D, Tetsch L, Lüftl M, Biedermann T. Extragenital cutaneous warts - clinical presentation, diagnosis and treatment. J Dtsch Dermatol Ges. 2019 Jun;17(6):613-634. doi: 10.1111/ddg.13878. — View Citation

Kwok CS, Holland R, Gibbs S. Efficacy of topical treatments for cutaneous warts: a meta-analysis and pooled analysis of randomized controlled trials. Br J Dermatol. 2011 Aug;165(2):233-46. doi: 10.1111/j.1365-2133.2011.10218.x. Epub 2011 May 26. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the change in size of plantar wart	measurement the change in size of plantar wart	3 month
Primary	the change in number of plantar warts	measurement the change in number of plantar warts	3 month